Clinical Trial Update: Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating toripalimab as postoperative therapy after surgical resection in high-risk stage IA2-IB non-small cell lung cancer without EGFR/ALK d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: NSCLC | Phase 2 | Status: RECRUITING